Skip to main content

Table 1 FDA approved cancer immunotherapies (including immune checkpoint therapies and adoptive cell therapies)

From: Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy

Category Target Name Indication Source
Immune Checkpoint Therapeutic (ICI) PD-1 or PD-L1 Nivolumab (Opdivo) Various cancers (e.g., Melanoma, Non-Small Cell Lung Cancer, etc.) (1)
  Pembrolizumab (Keytruda) Various cancers (e.g., Melanoma, classical Hodgkin Lymphoma, Primary Mediastinal B-cell Lymphoma, etc.) (2)
  Atezolizumab (Tecentriq) Non-Small Cell Lung Cancer, Urothelial Carcinoma, and Breast Cancer (3)
  Cemiplimab (Libtayo) Cutaneous Squamous Cell Carcinoma (4)
  Durvalumab (Imfinzi) Non-Small Cell Lung Cancer (5)
  Avelumab (Bavencio) Merkel Cell Carcinoma, and Urothelial Carcinoma (6)
CTLA4 Ipilimumab (Yervoy) Melanoma, Renal Cancer, and MSI (7)
Chimeric Antigen Receptor
Therapy (CAR-T)
CD19 Axicabtagene ciloleucel (Yescarta) Non-Hodgkin Lymphoma (8)
  Tisagenlecleucel (Kymriah) Non-Hodgkin Lymphoma (9)
  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.